pemetrexed accord pemetrexed (as disodium) 1000 mg powder for injection vial
accord healthcare pty ltd - pemetrexed disodium, quantity: 1102.9 mg (equivalent: pemetrexed, qty 1000 mg) - injection, powder for - excipient ingredients: hydrochloric acid; mannitol; sodium hydroxide - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.
pemetrexed accord pemetrexed (as disodium) 500 mg powder for injection vial
accord healthcare pty ltd - pemetrexed disodium, quantity: 551.45 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: hydrochloric acid; mannitol; sodium hydroxide - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.
pemetrexed-pf
viatris limited - pemetrexed disodium hemipentahydrate 604.12mg equivalent to pemetrexed 500 mg - powder for infusion - 500 mg - active: pemetrexed disodium hemipentahydrate 604.12mg equivalent to pemetrexed 500 mg excipient: hydrochloric acid mannitol sodium hydroxide - malignant pleural mesothelioma pemetrexed infusion is indicated for the treatment of patients with malignant pleural mesothelioma in combination with cisplatin.
pemetrexed pfizer (previously pemetrexed hospira)
pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
pemetrexed krka
krka d.d. - pemetrexed disodium - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesotheliomapemetrexed krka in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed krka in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.pemetrexed krka is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.pemetrexed krka is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
pemetrexed disodium for injection powder for solution
jamp pharma corporation - pemetrexed (pemetrexed disodium) - powder for solution - 100mg - pemetrexed (pemetrexed disodium) 100mg
pemetrexed disodium for injection powder for solution
jamp pharma corporation - pemetrexed (pemetrexed disodium) - powder for solution - 500mg - pemetrexed (pemetrexed disodium) 500mg
dbl pemetrexed pemetrexed (as disodium) 1000 mg powder for injection vial
pfizer australia pty ltd - pemetrexed disodium hemipentahydrate -
pemetrexed disodium for injection powder for solution
pfizer canada ulc - pemetrexed (pemetrexed disodium) - powder for solution - 100mg - pemetrexed (pemetrexed disodium) 100mg - antineoplastic agents
pemetrexed disodium for injection powder for solution
pfizer canada ulc - pemetrexed (pemetrexed disodium) - powder for solution - 500mg - pemetrexed (pemetrexed disodium) 500mg - antineoplastic agents